Last reviewed · How we verify
Catapresan
Catapresan, marketed by Odense University Hospital, is a drug with a well-established presence in its therapeutic area. The key composition patent for Catapresan is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk to Catapresan is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Catapresan |
|---|---|
| Also known as | Clonidine |
| Sponsor | Odense University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine (PHASE3)
- Premedication in Children: a Clinical Trial Comparing Oral Ketamine and Oral Clonidine With Respect to Sedation Level and Opioid Consumption in Pediatrics Undergoing Elective Lower Abdominal Day-case Surgery. (NA)
- Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients (PHASE2)
- Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty (PHASE4)
- Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study (PHASE1)
- Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder (PHASE4)
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |